• Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it started an underwritten public offering of 3.3 million shares of its common stock. The company said it intends to use the net proceeds from the offering to fund the ongoing clinical development of eravacycline and for working capital and other general corporate purposes.